Skip to main content
2015

SQI Diagnostics to Announce Fourth Quarter and Fiscal 2015 Results

By November 25, 2020No Comments

Toronto, OntarioDecember 10, 2015SQI Diagnostics Inc. (“SQI” or the “Company”) (TSX-V: SQD; OTCQX: SQIDF),

Toronto, Ontario, December 10, 2015 SQI Diagnostics Inc. (“SQI Diagnostics” or the “Company”) (TSX-V: SQD; OTCQX: SQIDF), today announced that it plans to release its financial and operational results the fourth quarter and fiscal year ended September 30, 2015, after market close on Wednesday, December 16, 2015. President and CEO, Andrew Morris, along with Company management, will host a conference call on Thursday December 17, 2015 at 10:00 a.m. ET to review financial results and discuss business developments for the period.

Conference Call Details:
Date:Thursday, December 17, 2015
Time:10:00 a.m. ET
Live Call:1-888-231-8191 (Canada and the United States)
Conference ID:5390230
Webcast:http://event.on24.com/r.htm?e=1107519&s=1&k=C64D95C270DFFC2F048CE807EF3ED066

An archived copy of the conference call will be available for 90 days on the Company website at www.sqidiagnostics.com/about/investors and also at http://event.on24.com/r.htm?e=1107519&s=1&k=C64D95C270DFFC2F048CE807EF3ED066.

Detailed financial statements and the management’s discussion and analysis (MD&A) will also be made available on the Company website at www.sqidiagnostics.com and at www.sedar.com.

For more information, please contact:

Chief Executive Officer
Andrew Morris
416.674.9500 ext. 229
amorris@sqidiagnostics.com

Chief Financial Officer
Lennie Ryer
416.674.9500 ext. 241
lryer@sqidiagnostics.com

About SQI Diagnostics

SQI Diagnostics is a life sciences and diagnostics company that develops clinical grade multiplexed microarray and molecular assays run on its automated instrumentation for the pharmaceutical research, animal health, and clinical diagnostics markets. SQI develops custom research and diagnostic assays that are multiplexed; meaning the simplification, consolidation and automation of many individual tests into one. This increases sample throughput, reduces time, cost and chance for human error, and provides excellent data quality. For more information, please visit sqidiagnostics.com.

Forward-looking Statements

This press release contains certain words and statements, which may constitute “forward-looking statements” within the meaning of applicable securities laws. Such statements reflect the current views of the Company with respect to future events and are subject to certain risks and uncertainties detailed in the Company’s ongoing filings with the securities regulatory authorities, available to the public at www.sedar.com. Actual results, events, and performance may differ materially. Readers are cautioned not to place undue reliance on these forward-looking statements. The Company undertakes no obligation to publicly update or revise any forward-looking statements either as a result of new information, future events or otherwise, except as required by applicable securities laws.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.